Drugs / 692342
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00950612 | Dec 2009 → Sep 2010 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00707967 | Jun 2008 → May 2009 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00600782 | Feb → Dec 2008 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 692342 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00600782 ↗ |
| Known as | M72/AS01 | “We evaluated the safety and immunogenicity of the candidate TB vaccine M72/AS01 in adults with well controlled HIV infection on cART.” PMID 24911353 ↗ Jul 2014 |
| Known as | M72/AS01E | “In a phase II, double-blind randomized, controlled study (NCT00950612), two doses of M72/AS01E or placebo were administered intramuscularly, one month apart.” PMID 26072017 ↗ Jun 2015 |
| Modality | Vaccine | “candidate TB vaccine” NCT00600782 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT00600782 ↗ |